No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A collaborative transplant study report

Journal of the American Society of Nephrology

Volumn 17, Issue 11, 2006, Pages 3257-3262

  Opelz, Gerhard ^a   Zeier, Martin ^a   Laux, Gunter ^a   Morath, Christian ^a   Döhler, Bernd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; DRUG USE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURGICAL PATIENT; SURVIVAL; TREATMENT OUTCOME;

EID: 33750726741     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006050543     Document Type: Article

References (11)

1. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R: Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17: 889-999, 2006
2. Collaborative Transplant Study, University of Heidelberg, Germany. Available at: www.ctstransplant.org. Accessed May 30, 2006
3. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Am Stat Assoc 53: 457-481, 1958
4. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34: 187-220, 1972
5. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 53: 217-222, 1998
6. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153, 2000
7. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 1004-1010, 2002
8. Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362: 782-788, 2003
9. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7: 158-165, 1996
10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001